ORION OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.27 EUR | -0.22% |
|
-2.74% | -17.83% |
Presenter SpeechTuukka Hirvonen (Executives)Good morning, everyone, and welcome to this webcas...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
32.27
EUR
Average target price
39.2
EUR
Spread / Average Target
+21.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.83% | 4.86B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- ORNBV Stock
- News Orion Oyj
- Transcript : Orion Oyj, V.M.D. n.v./s.a. - M&A Call
